Skip to main content

Table 1 Patient information

From: Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?

Subjects Number Female/male Age (years) ± SD Type MS DMT
HC Total 10 4/6 40 ± 12   
1 Female 25
2 Female 49
3 Female 25
4 Female 46
5 Male 50
6 Male 42
7 Male 30
8 Male 39
9 Male 33
10 Male 60
MS Total 15 8/7 45 ± 16   
11 Female 73 PP-MS Untreated
12 Male 51 PP-MS Untreated
13 Male 56 PP-MS Untreated
14 Female 25 RR-MS Interferon beta-1a
15 Female 71 RR-MS Untreated
16 Female 24 RR-MS Glatiramer acetate
17 Female 49 RR-MS Glatiramer acetate
18 Male 30 RR-MS Interferon beta-1a
19 Male 48 RR-MS Natalizumab
20 Female 30 RR-MS Untreated
21 Female 32 RR-MS Untreated
22 Female 46 RR-MS Untreated
23 Male 45 RR-MS Untreated
24 Male 58 RR-MS Untreated
25 Male 32 RR-MS Untreated
  1. HC healthy controls, MS multiple sclerosis, PP-MS primary progressive MS, RR-MS relapsing-remitting MS, SD standard deviation, DMT disease-modifying therapies